RGNX Stock Analysis: Regenxbio | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 533m USD | 12M Return: -31.5% | US75901B1070 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.1M
Qual. Beats: 1
Rev. Trend: 63.5%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
REGENXBIO Inc. (NASDAQ: RGNX) is a clinical-stage biotechnology company headquartered in Rockville, Maryland, that develops gene therapies for diseases caused by genetic defects. The company was incorporated in 2008 and went public in 2015, and is classified within the Health Care sectors Biotechnology sub-industry.
The companys pipeline is built on its proprietary NAV Technology Platform, an adeno-associated virus (AAV) gene delivery system used to transport functional genes into cells. Clinical-stage biotech firms like REGENXBIO typically have no approved products and rely on partnerships, grants, and capital markets to fund development until commercialization. Key pipeline candidates include ABBV-RGX-314 (in collaboration with AbbVie) for wet age-related macular degeneration and diabetic retinopathy, RGX-202 for Duchenne muscular dystrophy, RGX-121 for mucopolysaccharidosis type II, and RGX-111 for mucopolysaccharidosis type I.
In addition to its internal pipeline, REGENXBIO licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies, creating a royalty and milestone-based revenue stream alongside its partnered programs with AbbVie (global rights to ABBV-RGX-314) and Nippon Shinyaku (rights to RGX-121 and RGX-111 outside the United States). Platform-licensing arrangements are a common business model in the gene therapy sector, allowing companies to monetize their core delivery technology while focusing internal resources on priority clinical programs.
- ABBV-RGX-314 wet AMD pivotal trial data readout
- Cash burn raises dilution risk for small-cap biotech
- AbbVie partnership milestone payments offset operating losses
| Net Income: -196.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.65 > 0.02 and ΔFCF/TA -48.97 > 1.0 |
| NWC/Revenue: 88.00% < 20% (prev 163.2%; Δ -75.19% < -1%) |
| CFO/TA -0.64 > 3% & CFO -246.7m > Net Income -196.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (53.0m) vs 12m ago 2.98% < -2% |
| Gross Margin: 54.22% > 18% (prev 79.94%; Δ -25.71% > 0.5%) |
| Asset Turnover: 36.06% > 50% (prev 26.81%; Δ 9.25% > 0%) |
| Interest Coverage Ratio: -3.68 > 6 (EBIT TTM -154.5m / Interest Expense TTM 41.9m) |
| A: 0.40 (Total Current Assets 236.2m - Total Current Liabilities 82.6m) / Total Assets 386.6m |
| B: -3.09 (Retained Earnings -1.19b / Total Assets 386.6m) |
| C: -0.32 (EBIT TTM -154.5m / Avg Total Assets 483.8m) |
| D: 0.23 (Book Value of Equity 71.8m / Total Liabilities 314.9m) |
| Altman-Z'' = -9.36 = D |
| DSRI: 3.0 (Receivables 106.8m/21.5m, Revenue 174.5m/155.8m) |
| GMI: 1.47 (GM 79.94% / 54.22%) |
| AQI: 0.27 (AQ_t 0.02 / AQ_t-1 0.08) |
| SGI: 1.12 (Revenue 174.5m / 155.8m) |
| TATA: 0.13 (NI -196.4m - CFO -246.7m) / TA 386.6m) |
| Beneish M = -1.28 (Cap -4..+1) = D |
As of October 13, 2026, the stock is trading at USD 7.77 with a total of 2,033,251 shares traded. Over the past week, the price has changed by +0.13%, over one month by -10.59%, over three months by -39.06% and over the past year by -31.48%.
Current recommended Stop Loss: 7.00 (which is 9.9% or 1.4 ATR below the current price).
Regenxbio has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy RGNX.
- StrongBuy: 7
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 23.6 | 203.5% |
P/S = 3.0532
P/B = 6.8943
P/EG = 0.26
Revenue TTM = 174.5m USD
EBIT TTM = -154.5m USD
EBITDA TTM = -139.1m USD
Long Term Debt = 61.6m USD (estimated: total debt 69.0m - short term 7.36m)
Short Term Debt = 7.36m USD (from shortTermDebt, last quarter)
Debt = 69.0m USD (from shortLongTermDebtTotal, last quarter) (leases 69.0m already included)
Net Debt = -36.6m USD (calculated: Debt 69.0m - CCE 105.5m)
Enterprise Value = 496.2m USD (532.7m + Debt 69.0m - CCE 105.5m)
Interest Coverage Ratio = -3.68 (Ebit TTM -154.5m / Interest Expense TTM 41.9m)
EV/FCF = -1.99x (Enterprise Value 496.2m / FCF TTM -249.7m)
FCF Yield = -50.32% (FCF TTM -249.7m / Enterprise Value 496.2m)
FCF Margin = -143.1% (FCF TTM -249.7m / Revenue TTM 174.5m)
Net Margin = -112.6% (Net Income TTM -196.4m / Revenue TTM 174.5m)
Gross Margin = 54.22% ((Revenue TTM 174.5m - Cost of Revenue TTM 79.9m) / Revenue TTM)
Gross Margin QoQ = none% (prev -73.22%)
Tobins Q-Ratio = 1.28 (Enterprise Value 496.2m / Total Assets 386.6m)
Interest Expense / Debt = 60.83% (Interest Expense 41.9m / Debt 69.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -122.0m (EBIT -154.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.86 (Total Current Assets 236.2m / Total Current Liabilities 82.6m)
Debt / Equity = 0.96 (Debt 69.0m / totalStockholderEquity, last quarter 71.8m)
Debt / EBITDA = 0.26 (negative EBITDA) (Net Debt -36.6m / EBITDA -139.1m)
Debt / FCF = 0.15 (negative FCF - burning cash) (Net Debt -36.6m / FCF TTM -249.7m)
Total Stockholder Equity = 89.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.60% (Net Income -196.4m / Total Assets 386.6m)
RoE = -220.1% (Net Income TTM -196.4m / Total Stockholder Equity 89.3m)
RoCE = -102.4% (out of range, set to none) (EBIT -154.5m / Capital Employed (Equity 89.3m + L.T.Debt 61.6m))
RoIC = -40.33% (negative operating profit) (NOPAT -122.0m / Invested Capital 302.6m)
WACC = 12.86% (E(532.7m)/V(601.7m) * Re(14.52%) + (debt cost/tax rate unavailable))
Discount Rate = 14.52% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 79.06 | Cagr: 6.79%
[DCF] Fair Price = unknown (Cash Flow -249.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.10 | # QB: 1
Revenue Correlation: 63.45 | Revenue CAGR: 25.29% | SUE: 1.16 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-1.30 | Chg30d=-2.47% | Revisions=+22% | Analysts=9
EPS current Year (2026-12-31): EPS=-3.49 | Chg30d=+0.75% | Revisions=+10% | GrowthEPS=+7.1% | GrowthRev=-4.0%
EPS next Year (2027-12-31): EPS=-2.98 | Chg30d=+0.94% | Revisions=+30% | GrowthEPS=+14.8% | GrowthRev=+22.4%
[Analyst] Revisions Ratio: +26% (up=13, down=7)